Cancer: Crosetto's Breakthrough Inventions with Potential to Save Millions of Lives and Billions of Dollars Approved for a Two-Hour Presentation at IEEE

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Crosetto-Cancer

More Like This

Only Transparency and Accountability Can Save CERN: Stop Billions in Waste, Unlock Life-Saving Innovations

PR Newswire associated0

Dr Massimo Cristofanilli, MD Joins Datar Cancer Genetics as Strategic Advisor

NeutroFlow: Leading European Medical Consortium Awarded €2.5 Million Grant from EIC Transition Programme to Advance Predictive Biomarker Development for Immunotherapy Response

The CTIONCOTEST™ platform by CTIBIOTECH is an innovative 3D bioprinting technology that revolutionizes preclinical cancer research . It provides an automated, industrial-scale process to produce high-throughput, patient-specific human "microtumors" directly from primary tumor cells . Designed to tackle the 95% clinical failure rate of new cancer drugs, it faithfully replicates the complex tumor microenvironment, including critical hypoxic and necrotic zones . Targeting high-mortality breast, colon, and pancreatic cancers, the platform features three complexity levels: standard (cancer cells), intermediate (+fibroblasts), and advanced (+immune/endothelial cells) . A key breakthrough is its record cellular viability of 128 days, enabling unprecedented long-term studies on drug resistance and metastasis . Ultimately, CTIONCOTEST delivers a highly predictive, 100% human-derived ethical alternative to animal testing.

Printing the Future of Oncology: CTIBIOTECH Invests €3M and Secures €1.25M from France 2030 to Revolutionize Personalized Cancer Care

One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie

Together with Siemens Healthineers, Varian Showcases Commitment to Embracing Innovation and Enhancing Outcomes at ESTRO 2024

PR Newswire associated0

Caristo's Technology to be Featured in Non-Contrast CT and Late-Breaking Stroke Prediction Data at ESC 2026

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway